Deep Roots Chiropractic Health Center Offers Natural Pain Management in Bentonville
Tired of waking up feeling like your spine lost a fight with your mattress? You're not alone—and you're not out of luck. Deep Roots Chiropractic Health Center in Bentonville is helping locals say goodbye to chronic pain and hello to natural, drug-free relief.
Conveniently located at 103 SW Winsted Ln Suite 25, Deep Roots NWA is quickly becoming the go-to clinic for people who want real solutions—not just symptom patches. As a trusted back pain chiropractor in Bentonville, the team focuses on treating the root cause of pain so you can feel better—and stay that way.
'We don't hand out quick fixes,' said Dr. Ryan Carlson of Deep Roots Chiropractic Health Center. 'We help people reclaim their health with long-term solutions that actually work.'
Whether you're dealing with back, neck, or shoulder pain—or just feel like your body's been sending out distress signals—Deep Roots offers care that's customized, effective, and refreshingly honest. Their back and shoulder pain clinic approach blends gentle chiropractic adjustments with lifestyle support to help your body heal naturally.
What sets them apart?
From young professionals to busy parents to retirees, Bentonville residents are turning to Deep Roots for real results—and five-star care in a calm, welcoming space.
If your current routine includes painkillers, heating pads, and crossed fingers, it may be time to try something better.
To learn more or book your first visit, head over to www.deeprootsnwa.com.
Media Contact
Company Name: Deep Roots Health Center
Contact Person: Dr. Ryan Carlson
Email: Send Email
Phone: 479-334-0219
Address: 103 SW Winsted Ln #25
City: Bentonville
State: AR
Country: United States
Website: https://www.deeprootsnwa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 hours ago
- CTV News
The real Paleo diet: Neanderthals dined on rotten meat and maggots, study suggests
Lead author Melanie Beasley captured this image of a "maggot mass" for a follow-up study related to the newly released paper. (Melanie Beasley via CNN Newsource) Neanderthals had a voracious appetite for meat. They hunted big game and chowed down on woolly mammoth steak as they huddled around a fire. Or so thought many archaeologists who study the Stone Age. Fresh meat was far from the only thing on the menu, according to a growing body of research that has revealed our archaic cousins ate a varied diet that included pulses and shellfish. Still, a chemical signature in Neanderthal remains that suggests robust meat eating — observed at higher levels than those seen in top predators such as lions and wolves — has puzzled researchers for decades. Now, new research hints at an unexpected Stone Age food. Maggots — the larvae of flies, which hatch in and feed on decaying animal tissue — may also have been a staple of prehistoric diets, a study published Friday in the journal Science Advances suggests. Lead author Melanie Beasley, an assistant professor of biological anthropology at Purdue University in West Lafayette, Indiana, found that a taste for maggots could explain a distinctive chemical signature detected in the bones of prehistoric humans, including Homo sapiens and Neanderthals, a species that went extinct 40,000 years ago. The findings back up a hypothesis that had been put forward by Beasley's coauthor John Speth, an anthropologist at the University of Michigan, who has for nearly a decade argued that putrid meat and fish would have formed a key part of prehistoric diets. His work was based on ethnographic accounts of the diets of indigenous groups, who he said found rotten meat and maggots acceptable fare. 'Not a lot of people took notice, because it was like this is an out-there idea. And there wasn't any data,' said Beasley, who heard Speth give a talk in 2017 and subsequently decided to test his hypothesis. Understanding past diets To understand past diets and where an animal sat in the ancient food chain, scientists study the chemical signature of different isotopes, or variants, of elements such as nitrogen or carbon, which are preserved in teeth and bones over thousands of years. Researchers first found in the 1990s that the fossilized bones of Neanderthals unearthed in Northern Europe had particularly elevated levels of the nitrogen-15 isotope, a chemical signature that suggests their meat consumption was on par with hypercarnivores such as lions or wolves. 'Grass will have one (nitrogen) value, but then the deer that eats the grass is going to have a higher value, and then the carnivore that eats the deer is going to have an even higher value,' Beasley explained. 'So you can track nitrogen through this trophic food web system.' Neanderthal remains, she said, had even higher nitrogen values than carnivores. This was puzzling, however, because modern-day humans, unlike wolves and lions, cannot stomach large quantities of lean meat. Overindulging in it can lead to a potentially lethal form of malnutrition in which the liver fails to break down the protein and rid the body of excess nitrogen. Known today as protein poisoning, the condition was more common among European explorers of North America — who dubbed the illness 'rabbit poisoning' or 'mal de caribou' — given that wild game was far leaner than today's farmed meat. Archaeologists believe that Neanderthals understood the importance of fatty nutrients, and, at least in one location in what's now Germany, processed animal bones on a large scale to extract the fat. Rotten meat might be higher in nitrogen than fresh tissue and may have been responsible for boosting nitrogen levels in Neanderthal bones, Speth's research has suggested. Not long after hearing Speth speak, Beasley, who was previously a postdoctoral fellow at the University of Tennessee, Knoxville, where she conducted research at its Forensic Anthropology Center, decided to investigate. The research facility, sometimes described as a body farm, was established to study how the human body decomposes. There, she analyzed nitrogen levels in the rotting tissue of donated human corpses left outdoors and the fly larvae that formed in the muscle tissue. The work, conducted over a two-year period, required a strong stomach, she said. Beasley found that nitrogen levels increased modestly over time in the human tissue. However, she observed much higher nitrogen levels in the fly larvae, suggesting that Neanderthals and early modern humans likely consumed animal meat laced with maggots on a regular basis. 'I started getting the (nitrogen) values back, and they were just astronomically high,' Beasley recalled. 'John (Speth) and I started talking: What if it's not just the putrid meat, but it's the fact that … they're never going to be able to prevent flies from coming and landing on the meat, and so fly larva just become part of the delicacy,' she said. The data from her work not only provides insight into the Neanderthal diet but also informs modern forensic science, with nitrogen levels in maggots that form in human corpses helping scientists pinpoint time since death, she noted. 'No brainer' It was a 'no brainer' that Neanderthals ate maggots, said Karen Hardy, a professor of prehistoric archaeology at the University of Glasgow in Scotland. Hardy, who wasn't involved in the study, said the authors provided a 'strong argument in favor of maggot consumption,' although such behavior is unlikely to be conclusively proven because maggot remains do not survive in the archaeological record. 'The surprise element is more to do with our Western perspective on what is edible and what is not,' she added. Today, at least 2 billion people worldwide are estimated to consume insects as part of traditional diets, according to the United Nations Food and Agriculture Organization. The study also noted that, according to historical accounts, many indigenous peoples such as the Inuit 'viewed thoroughly putrefied, maggot-infested animal foods as highly desirable fare, not starvation rations.' Many such groups, according to the study, 'routinely, often intentionally, allowed animal foods to decompose to the point where they were crawling with maggots, in some cases even beginning to liquify, and inevitably emitting a stench so overpowering that early European explorers, fur trappers, and missionaries were sickened by it.' Knud Rasmussen, a polar explorer from Greenland, recorded the following culinary experience, cited in the study, in his 1931 book 'The Netsilik Eskimos: Social Life and Spiritual Culture.' 'The meat was green with age, and when we made a cut in it, it was like the bursting of a boil, so full of great white maggots was it. To my horror my companions scooped out handfuls of the crawling things and ate them with evident relish. I criticised their taste, but they … said, not illogically: 'You yourself like caribou meat, and what are these maggots but live caribou meat? They taste just the same as the meat and are refreshing to the mouth.' The study also noted that maggots are not unknown in Western culinary traditions, noting the Sardinian cheese casu marzu is replete with the larvae of cheese skipper flies. Beasley said that Northern latitude groups still process these foods today and consume them safely when prepared following traditional practices. Limitations Beasley's research on modern-day corpses was exploratory and had several limitations, she cautioned. The work, which involved small sample sizes, focused on human muscle tissue, not the tissue or organs of animals that might have been hunted by Neanderthals. What's more, the fly larvae, which came from three different families, might have differed from those that existed in the late Pleistocene, which ended around 11,000 years ago. The study also didn't account for the wide variety of climates and temperatures that would have had an effect on stored meat in the Stone Age. She also added that the human body tissue wasn't cooked, processed or prepared in any way. Beasley has spoken with researchers in Alaska in the hopes of connecting with native groups that would be interested in sharing traditional food preparations. Her goal is to better understand how that might affect the nitrogen level. The new research has 'opened a fascinating line of inquiry' into the culinary practices of Stone Age hunter-gatherers such as Neanderthals, said Wil Roebroeks, professor emeritus of paleolithic archaeology at Leiden University in the Netherlands. He wasn't involved in the research. 'It certainly gives a fresh — if that is the right word here — perspective on Neanderthal and other Late Pleistocene humans' diets,' Roebroeks added.
Globe and Mail
13 hours ago
- Globe and Mail
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement * Death was reported to health authorities * Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Source: Sarepta Therapeutics, Inc.
Globe and Mail
14 hours ago
- Globe and Mail
Amberton University Completes Major Overhaul, Revamping 100% of Courses and Expanding Programs
New initiatives include innovative AI integration, career-focused curriculum, and expanded healthcare and business programs. Garland, Texas--(Newsfile Corp. - July 25, 2025) - Amberton University announced today the completion of a comprehensive overhaul, revamping all courses and significantly expanding its program offerings for the 2025-2026 academic year. To view an enhanced version of this graphic, please visit: This initiative includes innovative AI integration, a highly career-focused curriculum, and expanded healthcare and business programs. "All Amberton courses have been completely updated with modern, real-world skills and AI competencies," stated Dr. Carol A. Palmer, President of Amberton University. Established over 50 years ago, Amberton University is renowned for its affordable, flexible education tailored specifically for working adults. Major Curriculum Overhaul Amberton has updated every course offered, clearly defining industry-driven skills across key programs such as project management, finance, clinical mental health counseling, and school counseling. This strategic initiative enhances graduates' career readiness and significantly boosts their practical value to employers. A Leader in AI Literacy Amberton is among the first fully AI-literate campuses nationwide, integrating AI competencies into every course. Business courses emphasize AI-driven strategies, Finance courses incorporate AI-based financial analysis, and Counseling courses explore AI-assisted therapeutic interventions. The newly launched Master of Science in Applied Artificial Intelligence program emphasizes responsible and strategic AI implementation. Students gain practical, hands-on learning experiences through an interactive AI Testing Environment, building tangible portfolios that demonstrate their AI proficiency. New Degree Programs and Certificates Amberton has introduced four critical new degree programs aligned with market demands: Master of Science in Applied Artificial Intelligence Master of Healthcare Administration (MHA) - This program is designed for individuals aiming to excel in executive and managerial positions within the healthcare sector. MBA in Finance - Focusing on fintech, cryptocurrency, blockchain, and advanced financial analytics. Master of Science in Training & Development - Addressing the increasing demand for workforce training and digital education. Additionally, nine practical certificate programs have been added as pathways toward full degrees, tailored to immediate industry needs. Commitment to Affordable, Quality Education Amberton maintains its position as one of the most affordable institutions nationwide, clearly outlining a transparent tuition model on its website. By avoiding unnecessary infrastructure costs, Amberton provides affordability without compromising educational quality. Faculty Voices and Industry Expertise Amberton faculty incorporate professional expertise directly into their instruction: Dr. Don Hebbard, Counseling: "Our students graduate ready to immediately make a difference, both professionally and personally." Dr. Deborah Hill, Human Development: "We're providing education that's immediately relevant to the workforce, not just theory." Dr. Ron Norris, Healthcare Administration: "Amberton's new healthcare program fills a critical need for qualified leaders in a rapidly growing healthcare sector." Dr. John Sinclair, AI Program Coordinator: "Amberton's AI curriculum uniquely positions graduates to become ethical, innovative leaders in AI implementation." Dr. Ken Johnson, Clinical Mental Health: "We remain highly responsive to student needs, continuously improving our counseling program to reflect current mental health practices." Student Success and Outcomes "This major overhaul is not just an update. It's Amberton's commitment to preparing our students for success in a rapidly changing world," stated Dr. Palmer. "Our students deserve an education that makes practical sense, and that's exactly what Amberton delivers." Interested students and professionals can apply easily and at no cost via the university's streamlined admission portal.
